GlassScriptPhysician profile
Bita Adib Bagheri
NPI 1467493163
$1,508.07
in general payments reported to CMS, 2019-2025
20 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.11 · 2020: $84.08 · 2021: $66.93 · 2022: $122 · 2023: $278 · 2024: $358 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $218.41 | 2021-2025 | |
| Leo Pharma INC. | $203.34 | 2024-2025 | Adbry, Anzupgo |
| Pfizer INC. | $185.53 | 2020-2025 | |
| Biofrontera INC. | $147.27 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Abbvie INC. | $122.04 | 2023-2025 | Botox, Rinvoq |
| Novartis Pharmaceuticals Corporation | $80.76 | 2024-2025 | |
| Amgen INC. | $77.97 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $72.23 | 2023-2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $65.39 | 2025 | Zoryve |
| Incyte Corporation | $50.93 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $49.14 | 2024-2025 | Sotyktu |
| Organon LLC | $40.23 | 2025 | Vtama |
| Dermavant Sciences, INC. | $35.93 | 2024 | Vtama |
| Janssen Biotech, INC. | $35.29 | 2024 | Tremfya |
| Mayne Pharma Commercial LLC | $28.70 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $28.22 | 2022 | |
| Galderma Laboratories, L.P. | $20.55 | 2023 | |
| Lilly USA, LLC | $17.93 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.37 | 2019 | |
| Viiv Healthcare Company | $13.84 | 2024 | Cabenuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bita Bagheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.